Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Ovarian cancer cells that coexpress endogenous Rb and p16 are insensitive to overexpression of functional p16 protein

Abstract

Defects of the `Rb/cyclin D1/p16 pathway' have been shown to play a critical role in the development of virtually all human malignancies assessed. To determine the contribution of G1 phase cell cycle defects to ovarian tumorigenesis, we have examined a panel of normal and tumor ovarian tissues and ovarian cancer cell lines for the expression of Rb, p16 and cyclin D1 proteins. Unlike most types of human cancer whose development involves the loss of either Rb or p16 expression, we observed the coexpression of Rb, p16 and cyclin D1 in 82% of ovarian cancer tissues and cell lines. Furthermore, the growth and cell cycle distribution profiles of three ovarian cancer cell lines (ES-2, PA-1 and NIH OVCAR-3) that coexpressed Rb and p16, were found to be unaffected by adenoviral-mediated overexpression of functional p16 protein, indicating the existence of a defect(s) downstream from p16 in these cells. By contrast overexpression of ectopic p16 in the one ovarian cancer cell line (SK-OV-3) that expressed Rb but lacked p16 protein, resulted in a G1 growth arrest. These data suggest that defects of the `Rb/cyclin D1/p16 pathway', other than the loss of Rb or p16, may play a major role in the development of ovarian cancer.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 4
Figure 3

Similar content being viewed by others

References

  • Bartek J, Bartkova J and Lukas J . 1997 Exper Cell Res 237: 1–6.

  • Campbell IG, Beynon G, Davis M and Englefield P . 1995 Int J Cancer 63: 222–225.

  • Chenevix-Trench G, Kerr J, Friedlander MM, Hurst T, Sanderson B, Coglan M, Ward B, Leary J and Khoo SK . 1994 Am J Hum Genet 55: 143–149.

  • Craig C, Kim M, Ohri E, Wersto R, Katayose D, Li Z, Choi YH, Mudahar B, Srivastava S, Seth P and Cowan K . 1998 Oncogene 16: 265–272.

  • Dong Y, Walsh MD, McGuckin MA, Gabrielli BG, Cummings MG, Wright RG, Hurst T, Khoo SK and Parsons PG . 1997 Int J Cancer 74: 57–63.

  • Fang X, Jin X, Xu H-J, Liu L, Peng H-Q, Hogg D, Roth JA, Yu Y, Xu F, Bast RC and Mills GB . 1998 Oncogene 16: 1–8.

  • Gemma A, Takenoshita S, Hagiwara K, Okamoto A, Spillare EA, McMemamin MG, Hussain SP, Forrester K, Zariwala M, Xiong Y and Harris CC . 1996 Int J Cancer 68: 605–611.

  • Geradts J, Kratzke RA, Niehans GA and Lincoln CE . 1995 Cancer Res 55: 6006–6011.

  • Geradts J and Wilson PA . 1996 Am J Path 149: 15–20.

  • Gray-Bablin J, Zalvide J, Fox MP, Knickerbocker CJ, DeCaprio JA and Keyomarsi K . 1996 Proc Natl Acad Sci USA 93: 15215–15220.

  • He J, Olson JJ and James CD . 1995 Cancer Res 55: 4833–4836.

  • Hinds PW, Mittnacht S, Dulic V, Arnold A, Reed SI and Weinberg RA . 1992 Cell 70: 993–1006.

  • Hung W-C, Chai C-Y, Huang J-S and Chuang L-Y . 1996 Human Path 27: 1324–1328.

  • Jin X, Nguyen D, Zhang WW, Kyritsis AP and Roth JA . 1995 Cancer Res 55: 3250–3253.

  • Kanuma T, Nishida J-I, Gima T, Barrett JC and Wake N . 1997 Molec Carcinog 18: 134–141.

  • Krishan A . 1975 J Cell Biol 66: 188

  • Laemmli UK . 1970 Nature 227: 680–685.

  • Li SB, Schwartz PE, Lee W-H and Yang-Feng TL . 1991 J Natl Can Inst 83: 637–640.

  • Liu Y, Heyman M, Wang Y, Falkmer U, Hising C, Szekely L and Einhorn S . 1994 Int J Cancer 58: 663–667.

  • Marchini S, Codegoni AM, Bonazzi C, Chiari S and Broggini M . 1997 Br J Cancer 76: 146–149.

  • McCluskey LL, Chen C, Delgadill E, Felix JC, Muderspach LI and Dubeau L . 1999 Gynecol Oncol 72: 87–92.

  • Milde-Langosch K, Ocon E, Becker G and Loning T . 1998 Int J Can 79: 61–65.

  • Nieman TH, Trgovac TL, McGaughy VR, Lewandowski GS and Copeland LJ . 1998 Gynecol Oncol 69: 214–219.

  • Osborn RJ and Leach V . 1994 Br J Cancer 69: 429–438.

  • Otterson GA, Kratzke RA, Coxon A, Kim YW and Kaye FJ . 1994 Oncogene 9: 3375–3378.

  • Palmero I and Peters G . 1997 Cancer Sur 27: 351–367.

  • Radabaugh KJ, Biggs RB, Qureshi JA, Barrett AJ, Welch WR, Bell DA, Berkowitz RS and Mok SC . 1995 Oncogene 11: 1259–1254.

  • Ryan A, Al-Jehani RM, Mulligan KT and Jacobs IJ . 1998 Gynecol Oncol 68: 14–17.

  • Saito M, Helin K, Valentine MB, Griffith BB, William CL, Harlow E and Look AT . 1995 Genomics 25: 130–138.

  • Sakaguichi M, Fujii Y, Hirabayashi H, Yoon H-E, Komoto Y, Oue T, Kusafuka T, Okada A and Matsuda H . 1996 Int J Cancer 65: 442–445.

  • Sclafani RA and Schauer IE . 1996 J Invest Derm 1: 123–127.

  • Schultz DC, Vanderveer L, Buetow KH, Boente MP, Ozols RR, Hamilton TC and Godwin AK . 1995 Cancer Res 55: 2150–2157.

  • Schuyer M, van Staveren IL, Klijn JGM, van der Burg MEL, Stoter G, Henzen-Logmans SC, Foekens JA and Berns EMJJ . 1996 Br J Cancer 74: 1069–1073.

  • Sellers WR and Kaelin WG . 1997 J Clin Oncol 15: 3301–3312.

  • Serrano M, Hannon GJ and Beach D . 1993 Nature 366: 704–707.

  • Serrano M . 1997 Exper Cell Res 237: 7–13.

  • Sherr CJ . 1994 Cell 73: 1059–1065.

  • Shih Y-C, Kerr J, Liu J, Hurst T, Khoo S-K, Ward B, Wainwright B and Chenevix-Trench G . 1997 Int J Cancer 70: 508–511.

  • Sui L, Tokuda M, Ohno M, Hatase O and Hando T . 1999 Gynecol, Oncol 73: 202–209.

  • Taylor RR, Linnoila RI, Gerardts J, Teneriello MG, Nash JD, Park RC and Birrer MJ . 1995 Gynecol Oncol 58: 307–311.

  • Weinberg RA . 1995 Cell 81: 323–311.

  • Weintraub S, Prater CA and Dean DC . 1992 Nature 358: 259–261.

  • Wolf JK, Kim T-E, Fightmaster D, Bodurka D, Gershenson DM Mills G and Wharton JT . 1999 Gynecol Oncol 73: 27–34.

  • Wolfel T, Hauer M, Schneider J, Serrano M, Wolfel C, Klehmann-Hieb E, De Plaen E, Hankeln T, Meyer zum Buschenfelde K-H and Beach D . 1995 Science 269: 1281–1284.

  • Worsley SD, Ponder BAJ and Davies BR . 1997 Gynecol Oncol 64: 189–195.

  • Zuo L, Weger J, Yang Q, Goldstein AM, Tucker MA, Walker GJ, Hayward N and Dracopoli NC . 1996 Nature Genetics 12: 97–99.

Download references

Acknowledgements

We would like to thank Weiming Shen and Bryn Grimison for their technical assistance and the University of Colorado Tissue Procurement Core for providing the ovarian tissue samples. This work was funded by a Colorado Cancer League Fellowship to Dr Maria Todd.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Todd, M., Sclafani, R. & Langan, T. Ovarian cancer cells that coexpress endogenous Rb and p16 are insensitive to overexpression of functional p16 protein. Oncogene 19, 258–264 (2000). https://doi.org/10.1038/sj.onc.1203289

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1203289

Keywords

This article is cited by

Search

Quick links